HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Oral high-dose methotrexate with citrovorum factor rescue in metastastic squamous cell carcinoma of the lung.

Abstract
Thirteen patients with metastatic squamous cell cancer of the lung were treated, in a nonrandomized study, with an oral high-dose methotrexate and citrovorum factor rescue regimen. There was some response and/or stabilization of disease for at least three months in six (46%) of 13 cases. The median survival time of the study group was double (365 vs. 180 days) that of a retrospectively matched control group. This suggests a possible therapeutic effect of this treatment program in metastatic squamous cell cancer of the lung.
AuthorsK Tornyos, H Faust
JournalCancer (Cancer) Vol. 41 Issue 2 Pg. 400-2 (Feb 1978) ISSN: 0008-543X [Print] United States
PMID305283 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Leucovorin
  • Methotrexate
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Carcinoma, Squamous Cell (drug therapy)
  • Drug Therapy, Combination
  • Humans
  • Leucovorin (therapeutic use)
  • Lung Neoplasms (drug therapy)
  • Methotrexate (administration & dosage)
  • Middle Aged
  • Neoplasm Metastasis (drug therapy)
  • Remission, Spontaneous
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: